ImmunoPrecise Antibodies (NASDAQ:IPA) Stock Rating Reaffirmed by HC Wainwright

ImmunoPrecise Antibodies (NASDAQ:IPA – Get Rating)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They currently have a $9.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 171.90% from the stock’s previous close.

ImmunoPrecise Antibodies Stock Down 1.8 %

IPA opened at $3.31 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.10 and a quick ratio of 2.89. The business has a 50 day simple moving average of $4.33 and a 200-day simple moving average of $4.78. The stock has a market capitalization of $82.52 million, a P/E ratio of -3.85 and a beta of 0.60. ImmunoPrecise Antibodies has a 12 month low of $3.17 and a 12 month high of $6.50.

ImmunoPrecise Antibodies (NASDAQ:IPA – Get Rating) last posted its quarterly earnings results on Thursday, December 15th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.09). The business had revenue of $3.89 million during the quarter, compared to analyst estimates of $3.91 million. ImmunoPrecise Antibodies had a negative net margin of 126.00% and a negative return on equity of 39.89%. On average, equities analysts anticipate that ImmunoPrecise Antibodies will post -0.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ImmunoPrecise Antibodies

Hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP purchased a new position in ImmunoPrecise Antibodies in the 1st quarter valued at approximately $67,000. Gradient Capital Advisors LLC increased its position in ImmunoPrecise Antibodies by 34.0% during the third quarter. Gradient Capital Advisors LLC now owns 26,808 shares of the company’s stock worth $107,000 after buying an additional 6,808 shares in the last quarter. Cibc World Market Inc. purchased a new position in ImmunoPrecise Antibodies during the second quarter worth $183,000. Bank of America Corp DE increased its position in ImmunoPrecise Antibodies by 1,849.1% during the first quarter. Bank of America Corp DE now owns 57,517 shares of the company’s stock worth $295,000 after buying an additional 54,566 shares in the last quarter. Finally, Bank of Montreal Can increased its position in ImmunoPrecise Antibodies by 62.7% during the first quarter. Bank of Montreal Can now owns 140,454 shares of the company’s stock worth $718,000 after buying an additional 54,145 shares in the last quarter. 5.68% of the stock is owned by hedge funds and other institutional investors.

ImmunoPrecise Antibodies Company Profile

(Get Rating)

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes.